Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma.
Standard
Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma. / Billecke, Lisa; Murga-Penas, Eva-Maria; May, Annette M; Engelhardt, Monika; Nagler, Arnon; Leiba, Merav; Schiby, Ginette; Kröger, Nicolaus; Zustin, Jozef; Marx, Andreas; Matschke, Jakob; Tiemann, Markus; Goekkurt, Eray; Bokemeyer, Carsten; Schilling, Georgia.
in: ANTICANCER RES, Jahrgang 32, Nr. 5, 5, 2012, S. 2031-2034.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma.
AU - Billecke, Lisa
AU - Murga-Penas, Eva-Maria
AU - May, Annette M
AU - Engelhardt, Monika
AU - Nagler, Arnon
AU - Leiba, Merav
AU - Schiby, Ginette
AU - Kröger, Nicolaus
AU - Zustin, Jozef
AU - Marx, Andreas
AU - Matschke, Jakob
AU - Tiemann, Markus
AU - Goekkurt, Eray
AU - Bokemeyer, Carsten
AU - Schilling, Georgia
PY - 2012
Y1 - 2012
N2 - Extramedullary (EM) organ impairment in patients with multiple myeloma (MM) is a rare event, occurring mostly during disease relapse after high-dose chemotherapy with autologous or allogeneic stem cell transplantation. This manifestation is commonly associated with an unfavourable outcome. Previous studies suggested a correlation between the clinical course of patients with MM and EM and the cytogenetic findings, e.g. deletion of TP53 on 17p13.
AB - Extramedullary (EM) organ impairment in patients with multiple myeloma (MM) is a rare event, occurring mostly during disease relapse after high-dose chemotherapy with autologous or allogeneic stem cell transplantation. This manifestation is commonly associated with an unfavourable outcome. Previous studies suggested a correlation between the clinical course of patients with MM and EM and the cytogenetic findings, e.g. deletion of TP53 on 17p13.
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Aged, 80 and over
KW - Chromosome Deletion
KW - Chromosomes, Human, Pair 17
KW - Genes, p53
KW - Multiple Myeloma/complications/genetics/pathology
KW - Osteolysis/etiology
KW - Soft Tissue Neoplasms/genetics/pathology
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Aged, 80 and over
KW - Chromosome Deletion
KW - Chromosomes, Human, Pair 17
KW - Genes, p53
KW - Multiple Myeloma/complications/genetics/pathology
KW - Osteolysis/etiology
KW - Soft Tissue Neoplasms/genetics/pathology
M3 - SCORING: Journal article
VL - 32
SP - 2031
EP - 2034
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 5
M1 - 5
ER -